Key result
Type 2 diabetes mellitus promotes diabetic cardiomyopathy through metabolic aberrations including excessive fatty acid utilization, suppressed glucose oxidation, and impaired mitochondrial function.
This review highlights the role of altered myocardial substrate metabolism and energetics in the pathogenesis of diabetic cardiomyopathy and discusses potential therapeutic targets.
Answers are grounded in this paper and cite their sources.
Metabolic targets in diabetic cardiomyopathy merit exploration; leaves open whether modulating these pathways improves clinical outcomes.
Type 2 diabetes mellitus escalates the risk of heart failure partly via its ability to induce a cardiomyopathic state that is independent of coronary artery disease and hypertension. Although the pathogenesis of diabetic cardiomyopathy has yet to be fully elucidated, aberrations in cardiac substrate metabolism and energetics are thought to be key drivers. These aberrations include excessive fatty acid utilisation and storage, suppressed glucose oxidation and impaired mitochondrial oxidative phosphorylation. An appreciation of how these abnormalities arise and synergise to promote adverse cardiac remodelling is critical to their effective amelioration. This review focuses on disturbances in myocardial fuel (fatty acids and glucose) flux and energetics in type 2 diabetes, how these disturbances relate to the development of diabetic cardiomyopathy and the potential therapeutic agents that could be used to correct them.
No takes yet. Share an insight, caveat, or question.
Amaral et al. (2015) conducted a review in Type 2 diabetes mellitus and diabetic cardiomyopathy. Type 2 diabetes mellitus promotes diabetic cardiomyopathy through metabolic aberrations including excessive fatty acid utilization, suppressed glucose oxidation, and impaired mitochondrial function.
Synapse has enriched 10 related papers. Consider them for comparative context: